TransMedicsNASDAQ: TMDX

Vertex Pharmaceuticals could have multiple new blockbusters on the way. Viking Therapeutics is targeting two massive markets -- obesity and NASH.

ANDOVER, Mass. , June 21, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on June 18, 2024, TransMedics granted non-qualified stock options to purchase an aggregate of 1,002 shares of its common stock and an aggregate of 657 restricted stock units to 1 employee, each as a material inducement for the employee's entry into employment with TransMedics.

ANDOVER, Mass. , May 17, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company revolutionizing organ transplant therapy for patients with end-stage lung, heart, and liver failure, announced on May 14, 2024, that it granted non-qualified stock options to purchase a total of 18,320 shares of its common stock and 12,068 restricted stock units to 8 employees as a significant incentive for their employment with the company.

Can TransMedics (TMDX) be a top stock choice for momentum investors? Let's investigate.

Zacks.com users have been closely monitoring TransMedics (TMDX) and it is important to be aware of the factors that could impact the stock's future performance.

TransMedics (TMDX) stock is on the rise and could continue to climb in the short term, thanks to strong earnings forecast adjustments.

TransMedics (TMDX) is currently trading at a year-long peak, but can investors anticipate further growth ahead? We examine the company's underlying factors for insight.

TransMedics Group, Inc. (NASDAQ:TMDX) held its Q1 2024 Earnings Conference Call on April 30, 2024 at 4:30 PM ET. Present at the call were Laine Morgan from Gilmartin Group, Waleed Hassanein, President & CEO, and Stephen Gordon, CFO. Conference call participants included Allen Gong from JPMorgan, Josh Jennings from TD Cowen, and Suraj Kalia from Oppenheimer & Company. The operator welcomed all participants to the call, which was in listen-only mode.

TransMedics (TMDX) reported earnings of $0.35 per share for the quarter, surpassing the Zacks Consensus Estimate of a loss of $0.05 per share. This is an improvement from a loss of $0.08 per share in the same quarter last year.